Inclusion Criteria:

- Diagnosis of MM, NHL, or HD.

- Eligible for a planned autologous peripheral stem cell transplantation.

- Written informed consent.

- At least 18 years of age (inclusive).

- Easter Cooperative Oncology Group (ECOG) performance status of 0-1.

- Adequate cardiac, renal, and pulmonary function sufficient to undergo apheresis and
transplantation, I.e., eligible by institutional standards for autologous stem cell
transplant.

- Male and female patients of childbearing potential agree to use appropriate form of
contraception (i.e., condom, diaphragm cervical cap, etc.) while on study and for at
least 3 months following the last treatment. Female patients of child-producing
potential must have a negative serum pregnancy test confirmed within 7 days of
beginning mobilization therapy.

- White blood cell (WBC) count greater than or equal to 2.5x10^9/L.

- Absolute neutrophil count (ANC) greater than or equal to 1.5x10^9/L.

- Platelet count greater than or equal to 100x10^9/L.

- Serum creatinine less than or equal to 2.2 mg/ dL.

- AST/SGOT, ALT/SGPT, and total bilirubin less than 2.5 x upper limit of normal (ULN).

Exclusion Criteria:

- History of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL),
acute myelocytic leukemia (AML), chronic myelocytic leukemia (CML), myelodysplastic
syndrome (MDS), plasma cell leukemia or other leukemia.

- Failed previous CD34+ cell collection attempts.

- Prior autologous or allogenic transplantation.

- less than 4 weeks since last anti-cancer therapy (including chemotherapy,
biologic/immunologic, radiation) or less than 6 weeks if prior therapy was with
nitrosourea or mitomycin (for therapies with prolonged effects, a treatment-free
interval of at least 2 half-lives should be considered) with the exception of the
following: Treatment with thalidomide, dexamethasone, lenalidomide (Revlimid®),
and/or bortezomib (Velcade®) is allowed up to 7 days prior to the first dose of G-CF.

- Bone marrow involvement greater than 20% assessed based on the most recent bone
marrow aspirate or biopsy.

- Treated with G-CSF or other cytokine within 14 days prior to the first dose of G-CSF
for mobilization.

- HIV positive.

- Active hepatitis B (positive HBsAg) or hepatitis C.

- Acute infection (febrile, i.e., temperature greater than 38 degrees Celsius/100.4
degrees Fahrenheit) within 24 hours prior to dosing or antibiotic therapy within 1
week of enrollment.

- Hypercalcemia as evidenced by greater than 1 mg/dL above ULN.

- Previously received investigational therapy with 4 weeks of enrolling in this
protocol or currently enrolled in another investigational protocol during the
mobilization phase.

- Central nervous system involvement including brain metastases of leptomeningeal
disease.

- Pregnant or nursing women.

- ECG or study result (exercize study, scan) indicative of previously undiagnosed
cardiac ischemia or a history of clinically significant rhythm disturbance
(arrhythmias), or other conduction abnormality in the last year that in the opinion
of the Investigator warrants exclusion of the subject from the trial.

- Co-morbid conditions(s), which in the opinion of the Investigator, renders the
patient at high risk from treatment complications or impairs their ability to comply
with the study treatment and protocol.